Tonix Pharmaceuticals Reports Q3 2026 Revenue Surge Driven by TONMYA Launch
Tonix Pharmaceuticals (TNXP) reported a significant increase in net product revenue for the third quarter of 2026, reaching $17.2 million compared to $3.3 million in the prior-year period. This growth was primarily driven by the commercial launch of TONMYA, which generated $15 million in sales and saw a 37% increase quarter-over-quarter due to expanded payer agreements and an increased sales force. Despite the revenue surge, the company reported a net loss of $53.3 million ($2.89 per share), up from a $32 million loss in Q3 2025. This widening loss is attributed to higher SG&A and R&D expenses related to the TONMYA launch and clinical programs. Management noted that current cash reserves of $162.8 million are expected to fund operations into early Q3 2027, suggesting a potential need for future financing.
Tickers: $TNXP
Topics: cash runway net loss prescriptions product launch revenue growth
Read the full article at Motley Fool
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)